Tyra Biosciences Inc (TYRA)
Healthcare
Biotechnology
31.90 $
-3.6%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Tyra Biosciences Inc (TYRA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 51.9% of the shares are freely tradable; institutional investors hold 111.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
111.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
2.9%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
51.9%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
30.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
60Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RA Capital Management, LLC | 20.51 | 12,198,625 | +0.0 | 03/31/2026 |
| FMR Inc | 13.03 | 7,747,648 | +61,570.4 | 03/31/2026 |
| Nextech Invest, Ltd. | 6.82 | 4,055,861 | +0.0 | 12/31/2025 |
| HHG PLC | 6.54 | 3,890,589 | +32.5 | 03/31/2026 |
| Alta Partners Management Company, L.P. | 6.43 | 3,823,425 | +0.0 | 03/31/2026 |
| Farallon Capital Management, L.L.C. | 6.02 | 3,580,818 | +73.3 | 03/31/2026 |
| TCG Crossover Management, LLC | 5.46 | 3,248,980 | +12.1 | 03/31/2026 |
| COMMODORE CAPITAL LP | 4.16 | 2,475,000 | -26.7 | 03/31/2026 |
| BlackRock Inc | 3.73 | 2,217,929 | +6.3 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity OTC | 5.51 | 3,279,300 | +24.5 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.